Table 1.
Overview of Data Sets
No. of Subjects with BPb |
|||||||||||||||||||
No. of Genetic Markersa |
Diagnostic and Ascertainment Criteria |
Narrow |
Broad |
||||||||||||||||
Data Set | Reference | Population | Race | No. of Pedigrees | No. ofGenotyped Individuals | Genotyped | Mapped | DiagnosticCriterion(a) | Diagnosisof Proband | Schemec | Diagnosis ofAffected Relatived | Total | ARP | FS | IF | Total | ARP | FS | IF |
Bonn | Cichon et al. 2001 | Germany, Israel, Italy | White | 75 | 387 | 389 | 386 | DSM-IIIR | BPI | 1SB | BPI, SAB, BPNOS, RUD | 103 | 62 | 45 | 27 | 124 | 98 | 69 | 36 |
Columbia | Liu et al. 2003 | Israel, U.S. | White | 40 | 358 | 334 | 333 | RDC | BPI, SAB | 2FD+ | BPI, SAB | 115 | 97 | 38 | 31 | 200 | 309 | 92 | 35 |
Johns Hopkins 1 | McInnis et al. 2003b | U.S. | Mixed | 63 | 562 | 823 | 802 | RDC | BPI | 2FD+ | BPI, BPII, SAB, RUD | 125 | 73 | 65 | 32 | 216 | 243 | 169 | 55 |
Johns Hopkins 2 | Fallin et al. 2004 | U.S. | White | 40 | 175 | 381 | 380 | DSM-IV | BPI | 1FD+ | BPI, BPII | 73 | 33 | 19 | 22 | 95 | 53 | 38 | 40 |
NIMH Wave 1 | NIMH Genetics Initiative Bipolar Group 1997 | U.S. | Mixed | 95 | 525 | 357 | 351 | DSM-IIIR, RDC | BPI | 1FD | BPI, SAB | 226 | 164 | 94 | 64 | 298 | 294 | 164 | 81 |
NIMH Wave 2 | Dick et al. 2002; McInnis et al. 2003a; Willour et al. 2003; Zandi et al. 2003 | U.S. | Mixed | 55 | 348 | 465 | 458 | DSM-IIIR, RDC | BPI | 1FD | BPI, SAB | 135 | 85 | 54 | 39 | 174 | 170 | 110 | 46 |
NIMH Wave 3 | Dick et al. 2003; NIMH Human Genetics Initiative Web Site | U.S. | Mixed | 220 | 982 | 372 | 372 | DSM-IV | BPI | 1SB | BPI, SAB | 489 | 310 | 254 | 189 | 534 | 370 | 288 | 193 |
NIMH Wave 4 | NIMH Human Genetics Initiative Web Site | U.S. | Mixed | 274 | 1,053 | 384 | 384 | DSM-IV | BPI | 1SB | BPI, SAB | 620 | 416 | 338 | 234 | 665 | 482 | 380 | 243 |
Portuguese | Pato et al. 2004 | Portugal | White | 16 | 102 | 346 | 342 | DSM-IV | BPI | 1FD | BPI, BPII, SAB | 43 | 35 | 27 | 15 | 44 | 37 | 27 | 15 |
UCSD | Kelsoe et al. 2001 | Canada, U.S. | White | 20 | 163 | 331 | 324 | DSM-IIIR | BPI, BPII | 2FD+ | BPI, BPII, SAB, RUD | 27 | 11 | 7 | 7 | 41 | 21 | 15 | 12 |
Wellcome Trust | Bennett et al. 2002 | Great Britain, Ireland | White | 151 |
509 |
380 |
378 |
DSM-IV | BPI | 1SB | BPI, BPII, BPNOS, RUD | 288 |
159 |
150 |
109 |
313 |
195 |
186 |
122 |
Total | 1,067 | 5,179 | 4,562 | 4,510 | 2,251 | 1,445 | 1,091 | 769 | 2,423 | 2,272 | 1,538 | 878 |
Genotyped=number of markers genotyped (autosomal only). Mapped=number of markers mapped to the common marker map (autosomal only).
ARP=all possible ARPs; FS=all possible full-sibling pairs ; IF=families informative for nonparametric allele-sharing linkage analysis.
Ascertainment scheme: 1SB=at least one affected sibling; 1FD=at least one affected first-degree relative; 1FD+=at least one affected first- or greater-degree relative; 2FD+=at least two affected first- or greater-degree relatives.
Diagnosis of the relative(s) of proband (satisfying ascertainment scheme). BPNOS=bipolar disorder–not otherwise specified.